PanCare4AYA is a large-scale EU-funded project that brings together 29 partners from 14 countries across Europe. The Princess Máxima Center, internationally recognized for its expertise in childhood and young adult cancer care, plays a central role in this effort to improve quality of life after cancer. It is led by Prof. Dr. Leontien Kremer, pediatrician and research group leader specialized in late effects after childhood cancer, and Dr. Heleen van der Pal, internist at the LATER outpatient clinic at the Máxima, where survivors of childhood cancer are monitored for long-term follow-up.
European guideline
The project will develop a Europe-wide guideline for follow-up care and screening tailored to the unique needs of AYA cancer survivors. It will also create easy-to-understand brochures and digital tools to help survivors and healthcare professionals apply these guidelines in practice.
A key part of the project is the AYA Cancer Survivor Screen program, which will be studied in 11 countries with 1,000 participants. This program includes personalized care plans, peer support networks, and training for healthcare providers. Researchers will study how the program affects survivors’ mental health, quality of life, and access to care. The program’s outcomes will form the basis to further improve care and follow-up for this unique patient group.
Bridging the gap
PanCare4AYA builds on the success of earlier projects focused on childhood cancer survivors and aims to bridge the gap between childhood and adult survivorship care. ‘The needs of AYA cancer survivors are different and often unmet,’ says Professor Kremer. ‘By connecting childhood and AYA cancer communities, we can learn from each other and improve care for cancer survivors aged 0 to 39.’
This important initiative reinforces the Máxima Center’s commitment to improving survivorship care and quality of life for young people affected by cancer across Europe.
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.
